Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SOAT1 | P35610 | 6/20 | 0.42 |
| ▸ | SOAT2 | O75908 | 1/20 | 0.40 |
| ▸ | ACAT1 | P24752 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3413695 | 0.89 | SOAT1 (0.52) | SOAT1SOAT2ACAT1MEN1KMT2A | |
| SCHEMBL3411313 | 0.87 | SOAT1 (0.43) | SOAT1SOAT2ACAT1ALDH1A1MEN1 | |
| SCHEMBL3408694 | 0.87 | SOAT1 (0.45) | SOAT1SOAT2ACAT1MEN1KMT2A | |
| SCHEMBL3407723 | 0.87 | SOAT1 (0.50) | SOAT1SOAT2ACAT1MEN1KMT2A | |
| SCHEMBL3409551 | 0.86 | SOAT1 (0.49) | SOAT1SOAT2ACAT1ALDH1A1MEN1 | |
| SCHEMBL3408287 | 0.84 | SOAT1 (0.45) | SOAT1SOAT2ACAT1 | |
| SCHEMBL3404084 | 0.84 | SOAT1 (0.48) | SOAT1SOAT2ACAT1ALDH1A1 | |
| SCHEMBL13243800 | 0.83 | SOAT1 (0.46) | SOAT1SOAT2ACAT1ALDH1A1 | |
| SCHEMBL3406376 | 0.80 | SOAT1 (0.47) | SOAT1SOAT2ACAT1MEN1KMT2A | |
| SCHEMBL3409114 | 0.79 | SOAT1 (0.46) | SOAT1SOAT2ACAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2197838-B1 | NOVEL PHENYLUREA DERIVATIVES, INHIBITORS OF THE ENZYME SOAT-1, AND PHARMACEUTICAL AND COSMETIC COMPOSITIONS CONTAINING THEM | GALDERMA RES & DEV (FR) | 2013-10-23 | — | — | EP | claimed |
| US-8394990-B2 | Phenylurea inhibitors of the enzyme SOAT-1 and pharmaceutical/cosmetic compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2013-03-12 | — | — | US | claimed |
| US-20100197735-A1 | NOVEL PHENYLUREA INHIBITORS OF THE ENZYME SOAT-1 AND PHARMACEUTICAL/COSMETIC COMPOSITIONS COMPRISED THEREOF | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2010-08-05 | — | — | US | claimed |
| EP-2197838-B1 | NOVEL PHENYLUREA DERIVATIVES, INHIBITORS OF THE ENZYME SOAT-1, AND PHARMACEUTICAL AND COSMETIC COMPOSITIONS CONTAINING THEM | GALDERMA RES & DEV (FR) | 2013-10-23 | — | — | EP | disclosed |
| US-8394990-B2 | Phenylurea inhibitors of the enzyme SOAT-1 and pharmaceutical/cosmetic compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2013-03-12 | — | — | US | disclosed |
| US-8394990-B2 | Phenylurea inhibitors of the enzyme SOAT-1 and pharmaceutical/cosmetic compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2013-03-12 | — | — | US | disclosed |
| US-8394990-B2 | Phenylurea inhibitors of the enzyme SOAT-1 and pharmaceutical/cosmetic compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2013-03-12 | — | — | US | disclosed |
| US-20100197735-A1 | NOVEL PHENYLUREA INHIBITORS OF THE ENZYME SOAT-1 AND PHARMACEUTICAL/COSMETIC COMPOSITIONS COMPRISED THEREOF | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2010-08-05 | — | — | US | disclosed |
| US-20100197735-A1 | NOVEL PHENYLUREA INHIBITORS OF THE ENZYME SOAT-1 AND PHARMACEUTICAL/COSMETIC COMPOSITIONS COMPRISED THEREOF | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2010-08-05 | — | — | US | disclosed |
| US-20100197735-A1 | NOVEL PHENYLUREA INHIBITORS OF THE ENZYME SOAT-1 AND PHARMACEUTICAL/COSMETIC COMPOSITIONS COMPRISED THEREOF | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2010-08-05 | — | — | US | disclosed |
| EP-2197838-A1 | NOVEL PHENYLUREA DERIVATIVES, INHIBITORS OF THE ENZYME SOAT-1, AND PHARMACEUTICAL AND COSMETIC COMPOSITIONS CONTAINING THEM | Galderma Research & Development (FR) | 2010-06-23 | — | — | EP | disclosed |
| WO-2009030746-A1 | NOVEL PHENYLUREA DERIVATIVES, INHIBITORS OF THE ENZYME SOAT-1, AND PHARMACEUTICAL AND COSMETIC COMPOSITIONS CONTAINING THEM | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2009-03-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197735-A1 | NOVEL PHENYLUREA INHIBITORS OF THE ENZYME SOAT-1 AND PHARMACEUTICAL/COSMETIC COMPOSITIONS COMPRISED THEREOF | SOAT1, SOAT2, ACAT2 | SOAT1 1/4885SOAT2 2/4885ACAT1 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.